Anticoagulation strategies post-PCI: NOAC choice and impact of reversal

Sponsored by Boehringer Ingelheim

Chairperson: S. Hohnloser

Learning Objectives

  • To learn about the latest data and ongoing developments regarding antithrombotic strategies in patients with atrial fibrillation (AF) post-PCI
  • To consider which factors are most important when choosing an oral anticoagulant, including key insights from emerging practice-based data
  • To be aware of the periprocedural PCI complications and the benefits of a specific NOAC reversal agent in these settings

Presentations available when logged in:

  • Session objectives
  • Advances in anticoagulation: impact on patients after coronary revascularisation
  • Safety, efficacy, control: choosing the right oral anticoagulant for our patients
  • Anticoagulation post-PCI in an AF patient: what could go wrong?
  • Session evaluation and key learnings